Apr 4, 2021 @ 9:52
Double whammy: Mike Navallo raises alarm over Ivermectin approval
Justice reporter and abogado, Mike Navallo has raised alarm over the impending approval of Ivermectin. The abogado said that this might affect the Department of Justice’s decision to charge those involved in Dengvaxia.
There’s a lot of debate on use of Ivermectin as cure and protection vs #COVID19. But it has yet to undergo enough clinical trials.
If govt approves its use, how will it reconcile DOJ’s decision to charge those involved in the Dengvaxia vaccine which underwent clinical trials?
— Mike Navallo (@mikenavallo) April 3, 2021
Navallo noted that Ivermectin is yet to undergo clinical trials despite the debate on its ability to cure and protect against COVID-19. The abogado said that this might draw some criticism since it’s barely getting a slap on the wrist compared to the Dengvaxia issue when that underwent clinical trials.
We all know how this story might end!